Antibody Targeted Amanitin Conjugates (ATACs)

Time: 10:10 am
day: Day Two

Details:

  • Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin
  • This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
  • Learn more about this technology platform that includes Amanitin supply, sitespecific conjugation, demonstrated safety profile and biomarker
  • HDP-101 is the first ATAC directed against BCMA entering Phase I trials in 2020

Speakers: